2025
Perspectives on Current Challenges and Emerging Approaches for the Management of CH, MDS, and AML From the 1st Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Carraway H, Brunner A, Lai C, Luskin M, Park J, Perl A, Stein E, Wang E, Zeidan A, Zeidner J, Komrokji R. Perspectives on Current Challenges and Emerging Approaches for the Management of CH, MDS, and AML From the 1st Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Clinical Lymphoma Myeloma & Leukemia 2025 PMID: 40187939, DOI: 10.1016/j.clml.2025.03.005.Peer-Reviewed Original ResearchManagement of myelodysplastic syndromesAcute myeloid leukemiaFrontline treatment of acute myeloid leukemiaTreatment of R/R AMLR/R acute myeloid leukemiaTreatment of acute myeloid leukemiaDevelopment of targeted therapiesSequence of therapyMonitoring of responseManagement of CHAssessment of responseMyelodysplastic syndromeClonal hematopoiesisFrontline treatmentMyeloid leukemiaEffective therapyClinical trialsMolecular testingCare of patientsConsensus recommendationsSelection of endpointsTreatment selectionTherapyPatientsLeukemia
2024
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Fathi A, Issa G, Wang E, Erba H, Altman J, Balasubramanian S, Roboz G, Schiller G, McMahon C, Palmisiano N, Juckett M, Madanat Y, Rotta M, Pratz K, Yaghmour G, Nadiminti K, Wei H, Riches M, Corum D, Leoni M, Dale S, Zeidan A. Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood 2024, 144: 2880-2880. DOI: 10.1182/blood-2024-199170.Peer-Reviewed Original ResearchAcute myeloid leukemiaDecreased neutrophil countDecreased platelet countNPM1 mutationsKMT2A-rAdverse eventsCRC ratesClinical activityR/R patientsData cutoffQTc prolongationPlatelet countMyeloid leukemiaNucleophosmin 1Neutrophil countDifferentiation syndromeComposite complete remission rateCycle 1 day 8R/R acute myeloid leukemiaTreatment-emergent adverse eventsDose of venetoclaxInhibitor-naive patientsDose-escalation cohortsDose-expansion phaseComplete remission ratePerspectives of Patients With Relapsed and Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome on Patient–Clinician Communication About Prognosis and the Future
Rao V, Linsky S, Knobf M. Perspectives of Patients With Relapsed and Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome on Patient–Clinician Communication About Prognosis and the Future. Palliative Medicine Reports 2024, 5: 53-62. PMID: 38249836, PMCID: PMC10797310, DOI: 10.1089/pmr.2023.0064.Peer-Reviewed Original ResearchPatient-clinician communicationHigh-risk myelodysplastic syndromeAcute myeloid leukemiaPerspectives of patientsMyelodysplastic syndromeU.S. cancer centersSemi-structured interviewsFog of uncertaintyMaintaining normalityDisease trajectoryMyeloid leukemiaPrognostic uncertaintyThematic analysisQualitative studyParticipants' perspectivesR/R acute myeloid leukemiaRefractory acute myeloid leukemiaCancer CenterLived experienceDay-to-day lived experiencesParticipantsHigh riskInterviewsHealthCommunication strategies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply